ATMI  launched a new technology for enabling large-scale, cell-based manufacturing as the company unveiled its Integrity™ Xpansion™ Bioreactor Systems at the Cell Therapy Manufacturing Conference in Brussels, Belgium. The new line of bioreactors are part of the ATMI LifeSciences Integrity family of single-use technologies and have been especially developed for fragile adherent cell culture applications (such as stem cells) on a large scale. The Integrity Xpansion product line represents the first commercially-available bioreactors that support safe and cost-efficient large-scale (large volume) production of traditional two-dimensional (2-D) cell cultures with the advantage of cell culture parameter controls.

 

 

 

- Compact and efficient, 2D multiplate design

 

 

 

- Scalable, single use closed system

 

 

 

- Cell Culture parameters control

 

 

 

- Cell Morphology and density monitoring

 

 

 

 

 

 

"It is essential that cell therapies can be made efficiently and effectively on a large scale for them to reach the market. Yet, it can be a challenge to achieve GMP standards during large-scale production because of a lack of efficient cell culture technologies — many of which can lead to bottlenecks and prohibitive costs," says Jose Castillo, the global director of cell culture technologies for ATMI LifeSciences. "The Xpansion bioreactors represent a solution for process industrialization for cell therapies. Both patient safety and GMP compliance have been factored into the system's design, as has operational simplicity. Space and cost requirements have been drastically reduced, enabling the user to operate in a manner that existing large-scale technologies cannot match."